tbuckley/cabot-search huggingface dataset:
Natural history and clinical prognosis of in situ mantle cell lymphoma.
Authors: Timothy Edward Kubal, Deniz Peker, Elizabeth Sagatys, Ling Zhang, Mojdeh Naghashpour, Lynn Moscinski, Eduardo M. Sotomayor, Lubomir Sokol, Celeste M. Bello, Jennifer L. Cultrera, Paul A. Chervenick, Bijal D. Shah
Journal: Journal of Clinical Oncology (2012)

e18506 Background: In-Situ Mantle Cell Lymphoma is a rare clinical entity that presents with involvement limited to the mantle zone of secondary follicles. Its true incidence may be underestimated and its natural history and clinical behavior remains poorly characterized given the small number of representative cases available in the literature. Current guidelines for patients diagnosed with In-Situ Mantle Cell Lymphoma advocate staging studies and close follow-up with treatment based on the clinical behavior of the disease. Methods: Database review of 204 patients diagnosed with Mantle Cell Lymphoma at Moffitt Cancer Center between May 1992 and December 2010 Results: Three cases of In-Situ Mantle Cell Lymphoma were found and analyzed. Patients 1 &amp; 2 had disease isolated to a single lymph node at diagnosis. In these cases, there were long latency periods of 5 and 9 years between initial resection of a single nodal site and later presentation with active, diffuse disease. Neither patient received therapy until progression with more advanced disease. Patient 2, who had a 9-year latency period was found to have complex cytogenetics suggesting evolution of the malignant clone during this prolonged latency period. Patient 3 presented with in situ disease in an inguinal node in conjunction with diffuse extranodal lung and forehead involvement, all noted at the time of diagnosis. Patient 1 obtained remission with Bendamustine &amp; Rituxamab. Patient 2 obtained remission with HyperCVAD and Autologous HSCT consolidation. Patient 3 obtained remission after R-CHOP. Patients 1 &amp; 2, both with long latency periods remain alive and free of disease, while patient 3 relapsed with extranodal disease 3 years after initial therapy. Conclusions: The natural history of In Situ-Mantle Cell Lymphoma varies with prolonged latency periods present in some patients. The genetic profile of the lymphoma may evolve during these latency periods portending a more aggressive clinical course at progression. Patients with newly diagnosed In-Situ Mantle Cell Lymphoma with no other evidence of active disease should be followed expectantly with therapy reserved for those patients whose disease progresses during followup.
Encouraging results from the Scottish alcohol brief intervention programme
Authors: Peter Rice
Journal: BMJ (2017)

McCambridge and Saitz regrettably make no mention of the Scottish alcohol brief intervention programme in their otherwise authoritative review.1 One of their criticisms is that “uptake is often low.” In Scotland 569 792 brief interventions were recorded as delivered between 2008 and 2015, with an estimated 43% of the potential …
EXOME SEQUENCING REVEALS NOVEL VARIANTS IN TMEM59L AND KLHL26 ASSOCIATED WITH A FAMILIAL CASE OF EBSTEIN'S ANOMALY AND LEFT VENTRICULAR NONCOMPACTION
Authors: Lauren North, Donna Mahnke, Karl Stamm, Huan Ling Liang, Richard J. Willes, Michele Frommelt, Michael Mitchell, Aoy Tomita-Mitchell
Journal: Journal of the American College of Cardiology (2017)
WP-1066, a Next-Generation Member of JAK-Stat Inhibitors, Induces Cell Cycle Arrest, Abrogates Proliferation, and Induces Apoptosis of Acute Myeloid Leukemia (AML) Cells.
Authors: Alessandra Ferrajoli, Stefan Faderl, Quin Van, David M. Harris, Waldemar Priebe, Hagop M. Kantarjian, Moshe Talpaz, Zeev Estrov
Journal: Blood (2004)
Safety and efficacy of thrombectomy in acute ischaemic stroke (REVASCAT): 1-year follow-up of a randomised open-label trial
Authors: Antoni Dávalos, Erik Cobo, Carlos A Molina, Angel Chamorro, M Angeles de Miquel, Luis San Román, Joaquín Serena, Elena López-Cancio, Marc Ribó, Mónica Millán, Xabier Urra, Pere Cardona, Alejandro Tomasello, Carlos Castaño, Jordi Blasco, Lucía Aja, Marta Rubiera, Meritxell Gomis, Arturo Renú, Blanca Lara, Joan Martí-Fàbregas, Brian Jankowitz, Neus Cerdà, Tudor G Jovin, M. Ribó, E. Sanjuan, M. Rubiera, J. Pagola, A. Flores, M. Muchada, P. Meler, E. Huerga, S. Gelabert, P. Coscojuela, A. Tomasello, D. Rodriguez, E. Santamarina, O. Maisterra, S. Boned, L. Seró, A. Rovira, C. Molina, M. Millán, L. Muñoz, N. Pérez de la Ossa, M. Gomis, L. Dorado, E. López-Cancio, E. Palomeras, J. Munuera, P. García Bermejo, S. Remollo, C. Castaño, R. García-Sort, P. Cuadras, P. Puyalto, M. Hernández-Pérez, M. Jiménez, A. Martínez-Piñeiro, G. Lucente, A. Dávalos, A. Chamorro, X. Urra, V. Obach, A. Cervera, S. Amaro, L. Llull, J. Codas, M. Balasa, J. Navarro, H. Ariño, A. Aceituno, S. Rudilosso, A. Renu, J.M. Macho, L. San Roman, J. Blasco, A. López, N. Macías, P. Cardona, H. Quesada, F. Rubio, L. Cano, B. Lara, M.A. de Miquel, L. Aja, A. Dávalos, T.G. Jovin, A. Chamorro, C. Molina, J. Serena, L. San Román, M.A. de Miquel, A. Rovira, E. Cobo, G. Albers, K. Lees, J. Arenillas, R. Roberts, M. Goyal, A.M. Demchuk, P Minhas, F Al-Ajlan, M Salluzzi, L Zimmel, S Patel, M Eesa, R. von Kummer, J. Martí-Fàbregas, B. Jankowitz, J. Serena, M. Salvat-Plana, E. López-Cancio, M. Hernandez-Pérez
Journal: The Lancet Neurology (2017)
HIGH-INTENSITY CULPRIT PLAQUE ON NONCONTRAST T1-WEIGTED MAGNETIC RESONANCE IMAGING AS A NOVEL DETERMINANT OF MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS AFTER PERCUTANEOUS CORONARY INTERVENTION
Authors: Kenji Matsumoto, Shoichi Ehara, Takao Hasegawa, Kenei Shimada
Journal: Journal of the American College of Cardiology (2017)
FDOPA Patterns in Adrenal Glands
Authors: Aurélie Moreau, Anne Laure Giraudet, David Kryza, Françoise Borson-Chazot, Claire Bournaud-Salinas, Thomas Mognetti, Jean-Christophe Lifante, Patrick Combemale, Francesco Giammarile, Claire Houzard
Journal: Clinical Nuclear Medicine (2017)

F-FDOPA is a well-established tool to explore pheochromocytomas. It tends to replace I-MIBG scan in metastatic pheochromocytomas, multiple endocrine neoplasia type 2-related tumors, succinate dehydrogenase [ubiquinone] iron-sulfur subunit-negative tumors, and succinate dehydrogenase[ZERO WIDTH SPACE]-positive lesions. To our knowledge, no study has characterized physiological and pathological adrenal glands with F-FDOPA from a quantitative point of view. We report the features of different normal and pathological adrenal glands with F-FDOPA. Within our series, only pheochromocytomas present a significantly increased uptake reflecting the high specificity of this tracer. Tumors such as adenomas or myelolipomas present no F-FDOPA significant accumulation. Interestingly, adrenal gland hyperplasia and solitary glands do not demonstrate compensatory uptake.
ACUTE AORTIC REGURGITATION POST-TRANSCATHETER AORTIC VALVE REPLACEMENT: IMPACT OF VARIOUS TREATMENT STRATEGIES
Authors: Ron Waksman, Edward Koifman, Hector Garcia-Garcia, Paul Corso, Sarkis Kiramijyan, Romain Didier, Nirav Patel, Arpi Tavil-Shatelyan, Arie Steinvil, Toby Rogers, Sandeep Kumar, Jiaxiang Gai, Rebecca Torguson, Itsik Ben-Dor, Augusto Pichard, Lowell Satler
Journal: Journal of the American College of Cardiology (2017)
PREVALENCE AND IN-HOSPITAL OUTCOMES OF UREMIC AND DIALYSIS PERICARDITIS: A UNITED STATES NATIONAL STUDY
Authors: Srikanth Yandrapalli, Gabriela Andries, Viswajit Reddy Anugu, Zeeshan Solangi, Sohaib Tariq, Pratik Mondal, Venkat Lakshmi Kishan Vuddanda, Wilbert Aronow, Sachin Sule, Howard Cooper, Savneek Chugh
Journal: Journal of the American College of Cardiology (2017)
Topotecan—Single agent activity in a weekly intravenous (IV) schedule for first-line therapy in poor prognosis extensive stage small cell lung cancer (SCLC): A Minnie Pearl Cancer Research Network phase II trial
Authors: P. B. Murphy, J. D. Hainsworth, D. R. Spigel, J. R. Gray, W. H. Liggett, D. L. Shipley, A. Switzer, J. G. Gandhi, C. L. Dannaher, F. A. Greco
Journal: Journal of Clinical Oncology (2006)

17000 Background: Topotecan IV weekly produces significantly less myelotoxicity than the standard 5-day IV schedule and appears as active in patients (pts) with relapsed ovarian cancer. Topotecan 5-day IV schedule is the standard for second-line therapy for pts with sensitive relapse SCLC. Methods: The primary endpoints were to determine the response rate and toxicity of weekly topotecan IV in pts with previously untreated extensive stage SCLC who were elderly, with poor performance status (PS), or severe coexistent medical illness. Topotecan 4mg/m 2 IV over 30 minutes for 12 consecutive weeks was planned. Dose modifications were made based on toxicity. Pts were evaluated for response after 4 weeks; at least 3 weekly treatments were required to be eligible. Results: 39 pts were enrolled: 21 men, 18 women; age range 60–90 (median 71); PS 0 = 2, 1 = 18, 2 = 19). 31 pts were evaluable by WHO criteria for response. 4 pts had partial responses (13%, 95% CI 4%-30%); 20 pts (65%) had stable disease (4 had minor responses with tumor shrinkage of 29%, 19%, 12%, and 5%); 7 pts had progressive disease (22%). 15 pts completed 12 weeks of therapy. Grade 3/4 neutropenia/thrombocytopenia was seen in 11 pts and 3 pts; grade 3 infection 4 pts; grade 3/4 fatigue 12 pts. A total of 225 weeks of therapy was administered with 32 weeks of treatment delay and 10% required dose reduction. There were no treatment-related deaths. The median and 1-year survival of PR/stable pts were 5.6 months and 24%. Conclusions: Topotecan IV weekly has activity and was relatively well tolerated as first-line therapy in this very poor prognostic group of pts with extensive stage SCLC. The therapeutic index is improved with weekly topotecan IV schedule in contrast to the 5-day IV schedule. Additional study of weekly topotecan in combination with other agents in SCLC is warranted. [Table: see text]
Climate change is harming Americans’ health, US doctors warn
Authors: Michael McCarthy
Journal: BMJ (2017)

Although most people in the US think of it as a distant threat, climate change is already harming their health, a consortium of 11 doctors’ groups warns in a new report. “We—physicians in medical societies representing over half of the nation’s doctors—see a need to share our growing understanding and concern about the health consequences of climate change with all Americans,” said their report, released Wednesday 15 March.1

The group, the Medical Society Consortium on Climate and Health, is composed of nine medical groups, including the …
The effect of two BRM promoter variants on the risk of stage I/II upper aerodigestive tract cancers.
Authors: Kit Man Wong, Xiaoping Qiu, Dangxiao Cheng, Abul Kalam Azad, Prakruthi R. Palepu, Maryam Mirshams, Devalben Patel, Zhuo Chen, Heidi Roberts, Jennifer J. Knox, Rebecca Wong, Gail Elizabeth Darling, John N Waldron, David P Goldstein, Natasha B. Leighl, Frances A. Shepherd, Ming Sound Tsao, Sandy Der, David Reisman, Geoffrey Liu
Journal: Journal of Clinical Oncology (2012)

10522 Background: BRM is a key subunit of the chromatin remodeling complex SWI/SNF and a putative tumor suppressor gene that is silenced in 15-20% of many solid tumors (PMID 15722796). Evidence suggests that it is epigenetically regulated, as two BRM promoter insertion variants (BRM-741 and BRM-1321) may lead to gene silencing by recruiting histone deacetylases. The presence of both homozygous BRM-741 and BRM-1321 highly correlate with loss of BRM expression and function in lung tumors, while increasing smoking-related lung cancer by two-fold (PMID 21478907). Also, the pharmacologic reversal of epigenetic changes of BRM offers a potential novel therapeutic approach (PMID 21478905). We assessed whether these BRM variants are associated with the risk of upper aerodigestive tract cancers, focusing on Stage I/II tumors that would most benefit from new screening and prevention strategies. Methods: BRM was genotyped by qPCR using TaqMan probes. 1,008 controls were matched to 595 cases by frequency distribution based on age, gender and smoking status. Multivariate logistic regression generated adjusted odds ratios (aOR). Results: The 595 cases were: 115 esophageal, 278 lung, and 202 head and neck cancers. 51% were adenocarcinomas; 60% were Stage I. The frequency of homozygozity was: BRM-741, 26%; BRM-1321, 23%; both variants, 15%. In the combined analysis, there was significant correlation between malignancy and homozygous BRM-741 (aOR 1.91 (95%CI 1.3-2.4); p=0.001) or BRM-1321 (aOR 1.94 (95%CI 1.4-2.7; p=3x10E-4). Being homozygous for both BRM variants carried an even greater risk (aOR 2.45 (95%CI 1.6-3.9); p=1x10E-5). This correlation was similar for adenocarcinomas (aOR 2.53 (95%CI 1.4-4.2); p=6x10E-4) and squamous cell carcinomas (aOR 2.33 (95%CI 1.3-4.4); p=8x10E-4). The increased cancer risk was also similar between these subgroups: head and neck, esophageal and lung cancers; Stage I and II patients; smokers and non-smokers. Conclusions: The two homozygous BRM variants increase the risk of early stage upper aerodigestive tumors by more than two-fold independent of smoking status. BRM promoter variants and their potential epigenetic effect may be early events in the evolution of these cancers.
Using survivorship care plans (SCP) to improve cancer communication and care coordination.
Authors: Deborah Mayer, Allison Mary Deal, Jeffrey M. Crane, Ronald C. Chen, Gary Asher, Laura Hanson, Stephanie B. Wheeler, Adrian Gerstel, Melissa Green, Donald Lee Rosenstein
Journal: Journal of Clinical Oncology (2015)

9580 Background: There is a need for closer collaboration between oncologists and primary care providers (PCP) to improve survivorship care. However, PCPs often feel unprepared to manage survivor needs. We conducted a pilot study to evaluate SCP +/- a coordinated PCP visit effect on confidence in survivorship care for patients (pt) and PCP. Methods: Pts completed baseline measures and then received a SCP after completing curative treatment during a scheduled post-treatment visit; half were randomized to attend a PCP visit within 30 days to review the SCP. Pre-Post measures for pts and PCPs included Confidence in Survivorship Information (CSI), Assessment of Survivor Concerns (general and cancer worries), Expectations for Care, and Patient Activation Measure. Wilcoxon signed-rank and rank sum tests were used for comparisons. Results: Pts (n = 34) were male (65%), age 57 (29-73), Caucasian (82%), and married (79%). PCPs (N = 30) were male (50%), age 48 (26-67), Caucasian (83%) with 19.5 years in practice (range 2-39); 52% were in family medicine. Patient: After receipt of the SCP, all pts had improved knowledge about next steps (p = 0.06) and less contradictory information about care (p < .0001). CSI and concerns improved after SCP receipt (p < 0.0001). While no significant differences at baseline, SCP benefits were greater in highly activated patients (n = 26) who had more CSI (p = 0.008) and less concerns (p = 0.007) than lower activated patients (n = 8). The general worry score rose for the controls and decreased for the intervention group (p = 0.05). At follow-up, most patients (82%) discussed with their oncologist being followed by them for cancer but only 32% discussed this with their PCP. Provider: PCPs reported improved CSI (p = 0.001) after receiving the SCP. They agreed it was their role to provide non-cancer related health care but were less clear about cancer surveillance and screening. Only 30% had discussions with pts’ other providers over who would follow cancer issues. Conclusions: SCP led to greater benefits for highly activated patients in CSI and concerns about cancer care; survivors who had a PCP visit after receiving the SCP had fewer worries than controls. PCP also had improved confidence in survivorship care after SCP receipt. Clinical trial information: UNC HENC LCCC 1325.
NOAC ADHERENCE OF THE PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION IN REAL PRACTICE
Authors: Han-Jun Bae, Seongwook Han, Sanghun Lee, Yun-Kyeong Cho, Yoon-Nyun Kim, Hyoung-Seob Park, Hyungseop Kim
Journal: Journal of the American College of Cardiology (2017)
Reply to letter on results of NRG Oncology RTOG 9813
Authors: Susan M. Chang, Arnab Chakavarti, Erica H. Bell
Journal: Neuro-Oncology (2017)

Additional criteria apply.Please refer to protocol 14379-201 for full inclusion and exclusion criteria.† Patients can participate if they had some skin cancers, superficial bladder cancer (cancer that was only on the surface of the lining of the bladder), or carcinoma in situ (cancer that had not spread) of the cervix or breast that had been cured.
The impact of patient navigation on racial and ethnic disparities: Results from the patient navigation research program.
Authors: Naomi Ko, Frederick Snyder, Peter C. Raich, Electra D. Paskett, Donald Dudley, Ji-Hyun Lee, Paul H. Levine, Karen M Freund
Journal: Journal of Clinical Oncology (2015)

6510 Background: Disparities in cancer outcomes for racial and ethnic minorities are an ongoing problem, in part due to persistent delays in timely care for at-risk patient populations. Patient navigation was developed to address barriers to timeliness. This study explores whether patient navigation reduces racial and ethnic disparities in timely cancer care. Methods: This is an analysis of the multi-site Patient Navigation Research Program. Participants were age 18 or older, had an abnormal cancer screening test, and were allocated to either the navigation arm or control arm (usual care). The outcome was time to diagnostic resolution of a screening abnormality. Unadjusted median time (25th, 75th percentile) to resolution was calculated for each racial/ethnic group by navigation and control. Multivariable Cox proportional hazards models were fit, adjusting for sex, age, cancer screening type, and health insurance, stratifying by center of care. Results: Among a sample of 7,514 participants, average age was 45.1, 89% were women, 43% Hispanic, 29% Non-Hispanic White (NHW) and 28% Black. Median time to resolution was similar across control and navigated arms for NHW patients [65 days (31, 220) for control and 67 days (33, 196) for navigation] and Hispanic patients [68 days (31, 208) and 62 days (34, 120)]. Black patients had longer median time to resolution in the control arm [108 days (42, 315)], still lagging in the navigated arm [97 days (49, 230)]. In the multi-variable adjusted models of the control arm, Black race was significantly associated with increased risk of delay (HR = 0.77; 95% CI: 0.69, 0.84) compared the NHW (reference) group. Hispanic race showed a non-significant increased risk (HR = 0.98; 95% CI 0.89, 1.07). There was borderline significance of an increased benefit of navigation among the navigated Hispanic group (HR 1.10; 95% CI: 0.998, 1.2), but a continued delay in diagnostic resolution among navigated Black patients (HR = 0.85; 95% CI: 0.77, 0.94) when compared to the NHW group. Conclusions: This study demonstrated significant delays in timely diagnostic care among Black participants. While navigation benefited minority groups, it did not eliminate all disparities in timely care for Black populations.
Half of NHS services do not provide recommended care for diabetic foot ulcers, shows audit
Authors: Susan Mayor
Journal: BMJ (2017)

Fewer than half of NHS local service commissioners provide all three care structures that the National Institute for Health and Care Excellence (NICE) recommends for patients with active diabetic foot disease, an audit of services in England and Wales has shown.

The audit collected data on 11 073 patients (mean age 67 years) who underwent expert assessment for diabetic foot ulcers for the first time between 14 July 2014 and 8 April 2016.1 They represented just over 13 000 new ulcer episodes at 173 specialist foot care services.

Just over half (116 of 216, 54%) of clinical commissioning groups (CCGs) in England and local health boards in Wales responded to the audit. Fifty of these (43%) reported that they had …
10-YEAR CARDIOVASCULAR RISK REDUCTION, EFFICACY AND SAFETY OF ALIROCUMAB AND EVOLOCUMAB, IN ADDITION TO MAXIMAL TOLERATED CHOLESTEROL LOWERING THERAPY: POST-COMMERCIALIZATION STUDY
Authors: Ilana Schlam, Ali Huda, Sarah H. Min, Christopher Mahida, Parth Shah, Ping Wang, Naila Goldenberg, Charles Glueck
Journal: Journal of the American College of Cardiology (2017)
Three-arm randomized phase II study of carboplatin (C) and paclitaxel (P) in combination with cetuximab (CET), IMC-A12, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508).
Authors: Nasser H. Hanna, Suzanne Eleanor Dahlberg, Jill Kolesar, Fred R. Hirsch, Suresh S. Ramalingam, Joan H. Schiller
Journal: Journal of Clinical Oncology (2012)

7516 Background: Pre-clinical evidence supports the clinical investigation of inhibitors to the insulin-like growth factor receptor (IGFR) and the epidermal growth factor receptor (EGFR) alone and in combination with one another in patients (pts) with NSCLC. Methods: Pts w/ chemotherapy-naïve, advanced NSCLC, not eligible for bevacizumab-based therapy, ECOG PS 0/1 were eligible. Pts with uncontrolled or untreated brain mets and/or severe hyperglycemia were ineligible. Pts were randomized to receive: C AUC 6 iv + P 200 mg/m2 iv on day 1 every 3 wks combined with either CET iv weekly (arm A), IMC-A12 iv every 2 wks (arm B), or both (arm C). Patients with non-progressive disease (PD) after 12 weeks of therapy were permitted to continue on maintenance antibody therapy until PD. The primary objective was PFS. Secondary objectives included OS and toxicity. The design required 180 eligible patients and had an 88% power to detect a 60% increase in median PFS for either comparison (arm A vs C or arm B vs C) (1-sided 0.10 level test). Results: Characteristics for arms A (n=39)/B (n=42)/C (n=48): males were 51%/57%/54%; median age was 60, 62, 60; PS 0 49%/52%/60%; stage IV 87%/83%/94%; adenocarcinoma 44%/26%/42%. The study was closed prematurely due to safety concerns after 129 eligible pts were treated. 13 patients died during treatment (A=6; B=2; C=5), including 9 w/in ~1 mo of starting therapy. G3-5 toxicities, all attributions, A/B/C: anemia 16%/7%/13%; neutropenia 27%/29%/42%; febrile neutropenia 7%/5%/4%; thrombocytopenia 7%/10%/13%; pneumonia 9%/2%/6%; hyperglycemia 2%/10%/15%; rash 5%/2%/8%; hyponatremia 2%/5%/17%; thromboembolic events 2%/10%/0%; fatigue 16%;22%/13%. The estimated median PFS and OS for arms A/B/C were 3.4, 4.3, and 4.1 mos and 11.7, 8.6, and 8.4 mos, respectively. Conclusions: Based upon apparent lack of efficacy and excessive premature deaths, this study does not support the continued investigation of C + T + IMC-A12 alone or in combination with CET in pts with advanced NSCLC not eligible for bevacizumab.